Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biologics
Brought to you by:
Biotech
Vicebio hauls in $100M series B to push RSV shot through phase 1
The respiratory syncytial virus space may have filled up over the past year, but that isn’t deterring Vicebio or its investors.
James Waldron
Sep 23, 2024 3:00am
Potential new Alzheimer's drugs target tangles of tau
Sep 19, 2024 2:42pm
New cell therapy biotech emerges from the lab of George Church
Sep 19, 2024 6:30am
Novo Nordisk signs $530M biobucks deal to sing in Korro's opera
Sep 16, 2024 9:40am
ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial
Sep 14, 2024 2:30am
Oncternal stock sinks 60% amid layoffs, trial terminations
Sep 12, 2024 10:51am